Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown in recent years?

The market size for seasonal influenza has seen significant expansion in recent times. The development from $8.41 billion in 2024 to $9.88 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 17.4%, signifies this rapid growth. Factors contributing to this growth during the historic period include an increase in influenza cases, a growing aging population, a surge in incidence of infectious and chronic diseases, an escalating burden of illness related to influenza, and a rise in respiratory infections.

How is the market size expected to evolve during the forecast period?

The market size of seasonal influenza is predicted to witness a swift expansion in the coming years. The growth is projected to reach $18.55 billion in 2029, with a compound annual growth rate (CAGR) of 17.1%. The increase in this forecasted period is due to the rising demand for oral drug solutions, enlarged research and development endeavors, growing vaccination numbers, improvements in healthcare infrastructure, and the escalated demand for retail pharmacies. The key trends anticipated during this forecast period encompass progress in treatment methods, technological advancements, strides in vaccine technology, mRNA technology, and the emergence of digital health strategies for tracking and diagnosis.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

What key factors are fueling the growth of the market?

The escalating incidence of infections affecting the respiratory system is predicted to drive the expansion of the seasonal influenza market. Such infections, brought about by viruses or bacteria, impact the respiratory tract, encompassing sinuses, throat, airways, and lungs. Factors such as air pollution, shifting climates, impaired immune system responses, and the easy spread of viruses in overcrowded or inadequately ventilated spaces contribute to this rising incidence. Seasonal influenza treatments contribute to the prevention or mitigation of the severity of these respiratory infections in numerous ways, predominantly via targeting the influenza virus and managing associated symptoms that could result in further infections. For instance, the UK Health Security Agency, a governmental entity from the UK, reported a year-on-year growth of 10.7% in tuberculosis (TB) cases (an infection of the respiratory tract caused by the bacterium Mycobacterium tuberculosis) in England in October 2024, escalating from 4,380 cases in 2022 to 4,850 cases. Consequently, the upsurge in respiratory infections is set to propel the growth of the seasonal influenza market.

What are the market segments in the industry?

The seasonal influenza market covered in this report is segmented –

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online

4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:

1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes

2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata

3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus

4) By Influenza D Virus: Animal-associated Influenza D

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which leading companies are shaping the growth of the market?

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

What key trends are currently impacting the market’s development?

Major companies in the seasonal influenza market are dedicating their efforts towards innovation, specifically in therapies like multi-disease vaccines, that augment the body’s resistance towards diverse virus strains, enhance the protection they offer, and cut down on the number of vaccinations necessary. Multi-disease vaccines, which guard against a variety of illnesses or strains using just one injection, substantially lessen the number of shots required for immunization. For example, in October 2023, Moderna, Inc., a biotechnology firm based in the United States, released positive interim results from its Phase 1/2 trial of mRNA-1083. This experimental united vaccine targets both influenza and COVID-19 and is currently under evaluation for its safety and the ability to stimulate an immune response in comparison with standard flu vaccines such as Fluarix (for age group 50-64) and Fluzone HD (for age group 65-79) as well as the Spikevax booster. mRNA-1083 is being developed with the intent to increase patient compliance, simplify the administration process, and convenience for both individuals and healthcare systems.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285

Which geographic areas are influencing the growth of the market?

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Biosimilar Growth Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Hormones Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: